0001140361-17-033255.txt : 20170825 0001140361-17-033255.hdr.sgml : 20170825 20170825140039 ACCESSION NUMBER: 0001140361-17-033255 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170825 DATE AS OF CHANGE: 20170825 EFFECTIVENESS DATE: 20170825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: eXIthera Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001554842 IRS NUMBER: 460548420 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-293500 FILM NUMBER: 171051508 BUSINESS ADDRESS: STREET 1: 1900 WEST PARK DRIVE STREET 2: SUITE 280 CITY: WESTBOROUGH STATE: MA ZIP: 01581 BUSINESS PHONE: 617-852-1960 MAIL ADDRESS: STREET 1: 1900 WEST PARK DRIVE STREET 2: SUITE 280 CITY: WESTBOROUGH STATE: MA ZIP: 01581 FORMER COMPANY: FORMER CONFORMED NAME: eXIthera Pharmaceuticals LLC DATE OF NAME CHANGE: 20120724 FORMER COMPANY: FORMER CONFORMED NAME: eXlthera Pharmaceuticals LLC DATE OF NAME CHANGE: 20120724 D 1 primary_doc.xml X0708 D LIVE 0001554842 eXIthera Pharmaceuticals, Inc. 1900 WEST PARK DRIVE SUITE 280 WESTBOROUGH MA MASSACHUSETTS 01581 617-852-1960 DELAWARE None eXIthera Pharmaceuticals LLC eXlthera Pharmaceuticals LLC Corporation true Neil J. Hayward c/o eXIthera Pharmaceuticals, Inc. 1900 West Park Drive, Suite 280 Westborough MA MASSACHUSETTS 01581 Executive Officer Director Mr. Hayward is the President and Chief Executive Officer of the Issuer. William Koster c/o eXIthera Pharmaceuticals, Inc. 1900 West Park Drive, Suite 280 Westborough MA MASSACHUSETTS 01581 Director Frans Stassen c/o eXIthera Pharmaceuticals, Inc. 1900 West Park Drive, Suite 280 Westborough MA MASSACHUSETTS 01581 Director Fred Meyer c/o eXIthera Pharmaceuticals, Inc. 1900 West Park Drive, Suite 280 Westborough MA MASSACHUSETTS 01581 Director Scott Yaphe c/o eXIthera Pharmaceuticals, Inc. 1900 West Park Drive, Suite 280 Westborough MA MASSACHUSETTS 01581 Director Biotechnology Decline to Disclose 06b false 2017-08-10 false true true true true true Secured Convertible Promissory Notes which may be converted into Series B Preferred Stock or other equity securities. false 0 5400000 3000000 2400000 The total offering amount includes the total amount of interest on the Secured Convertible Promissory Notes. false 2 0 0 0 false eXIthera Pharmaceuticals, Inc. /s/ Neil J. Hayward Neil J. Hayward President and Chief Executive Officer of the Issuer 2017-08-24